What if GLP-1 obesity drugs reshape food, drink and healthcare?
GLP-1 expansion is a relative-value rotation, not an index move (cascade is empty by design): long pharma/Novo-Lilly and healthcare volumes, short the calorie-and-comorbidity complex - packaged food, soda, alcohol, dialysis, bariatric. Rhymes with the Aug-2023 'Wegovy effect' selloff that knocked food/bev and medtech on the announcement. Forward angle: as oral and cheaper generics broaden access, the consumer-staples derating deepens while restaurants/apparel see mixed volume effects - it's a long-short within consumer, not a beta call.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. A blockbuster obesity/GLP-1 expansion reshapes food, beverage and healthcare sectors. The trigger decomposes into signed root‑shocks — Consumer spending ▼ · Growth surprise ▲ — which propagate through our causal graph to the markets below.